Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	voltage-gated sodium channel activity	CACNA1I SCN11A SCN2A SCN5A	1.63e-08	26	22	4	GO:0005248
GeneOntologyMolecularFunction	sodium channel activity	CACNA1I SCN11A SCN2A SCN5A	2.89e-07	52	22	4	GO:0005272
GeneOntologyMolecularFunction	sodium ion transmembrane transporter activity	CACNA1I SCN11A SCN2A SCN5A	3.37e-05	171	22	4	GO:0015081
GeneOntologyMolecularFunction	RNA polymerase II-specific DNA-binding transcription factor binding	MTA2 PRAMEF19 KDM5C MTA1 PRAMEF18	7.62e-05	417	22	5	GO:0061629
GeneOntologyMolecularFunction	DNA-binding transcription factor binding	MTA2 PRAMEF19 KDM5C MTA1 PRAMEF18	3.61e-04	582	22	5	GO:0140297
GeneOntologyMolecularFunction	monoatomic cation channel activity	CACNA1I SCN11A SCN2A SCN5A	4.90e-04	343	22	4	GO:0005261
GeneOntologyMolecularFunction	demethylase activity	KDM5C FTO	1.07e-03	44	22	2	GO:0032451
GeneOntologyMolecularFunction	transcription factor binding	MTA2 PRAMEF19 KDM5C MTA1 PRAMEF18	1.16e-03	753	22	5	GO:0008134
GeneOntologyMolecularFunction	monoatomic ion channel activity	CACNA1I SCN11A SCN2A SCN5A	1.45e-03	459	22	4	GO:0005216
GeneOntologyMolecularFunction	metal ion transmembrane transporter activity	CACNA1I SCN11A SCN2A SCN5A	1.52e-03	465	22	4	GO:0046873
GeneOntologyMolecularFunction	nuclear retinoic acid receptor binding	PRAMEF19 PRAMEF18	1.66e-03	55	22	2	GO:0042974
GeneOntologyMolecularFunction	histone modifying activity	MTA2 KDM5C KMT2D	1.95e-03	229	22	3	GO:0140993
GeneOntologyMolecularFunction	2-oxoglutarate-dependent dioxygenase activity	KDM5C FTO	2.31e-03	65	22	2	GO:0016706
GeneOntologyMolecularFunction	channel activity	CACNA1I SCN11A SCN2A SCN5A	2.37e-03	525	22	4	GO:0015267
GeneOntologyMolecularFunction	passive transmembrane transporter activity	CACNA1I SCN11A SCN2A SCN5A	2.39e-03	526	22	4	GO:0022803
GeneOntologyMolecularFunction	ubiquitin-like ligase-substrate adaptor activity	PRAMEF19 PRAMEF18	3.65e-03	82	22	2	GO:1990756
GeneOntologyMolecularFunction	transcription coactivator activity	MTA2 KMT2D MTA1	4.30e-03	303	22	3	GO:0003713
GeneOntologyMolecularFunction	inorganic cation transmembrane transporter activity	CACNA1I SCN11A SCN2A SCN5A	4.49e-03	627	22	4	GO:0022890
GeneOntologyMolecularFunction	enzyme-substrate adaptor activity	PRAMEF19 PRAMEF18	4.86e-03	95	22	2	GO:0140767
GeneOntologyMolecularFunction	dioxygenase activity	KDM5C FTO	5.17e-03	98	22	2	GO:0051213
GeneOntologyMolecularFunction	monoatomic cation transmembrane transporter activity	CACNA1I SCN11A SCN2A SCN5A	5.50e-03	664	22	4	GO:0008324
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	MTA2 PRAMEF19 KMT2D MTA1 PRAMEF18	7.54e-03	1160	22	5	GO:0030674
GeneOntologyMolecularFunction	ubiquitin protein ligase activity	DCST1 RFFL ASB1	7.59e-03	372	22	3	GO:0061630
GeneOntologyMolecularFunction	inorganic molecular entity transmembrane transporter activity	CACNA1I SCN11A SCN2A SCN5A	8.73e-03	758	22	4	GO:0015318
GeneOntologyMolecularFunction	ubiquitin-like protein ligase activity	DCST1 RFFL ASB1	9.13e-03	398	22	3	GO:0061659
GeneOntologyMolecularFunction	monoatomic ion transmembrane transporter activity	CACNA1I SCN11A SCN2A SCN5A	1.02e-02	793	22	4	GO:0015075
GeneOntologyMolecularFunction	histone deacetylase binding	MTA2 MTA1	1.13e-02	147	22	2	GO:0042826
GeneOntologyMolecularFunction	molecular adaptor activity	MTA2 PRAMEF19 KMT2D MTA1 PRAMEF18	1.43e-02	1356	22	5	GO:0060090
GeneOntologyMolecularFunction	ubiquitin-protein transferase activity	DCST1 RFFL ASB1	1.46e-02	473	22	3	GO:0004842
GeneOntologyBiologicalProcess	membrane depolarization during action potential	CACNA1I SCN11A SCN2A SCN5A	5.59e-08	36	22	4	GO:0086010
GeneOntologyBiologicalProcess	neuronal action potential	CACNA1I SCN11A SCN2A SCN5A	5.55e-07	63	22	4	GO:0019228
GeneOntologyBiologicalProcess	transmission of nerve impulse	CACNA1I SCN11A SCN2A SCN5A	5.59e-06	112	22	4	GO:0019226
GeneOntologyBiologicalProcess	membrane depolarization	CACNA1I SCN11A SCN2A SCN5A	7.60e-06	121	22	4	GO:0051899
GeneOntologyBiologicalProcess	cardiac muscle cell action potential involved in contraction	SCN11A SCN2A SCN5A	3.82e-05	62	22	3	GO:0086002
GeneOntologyBiologicalProcess	action potential	CACNA1I SCN11A SCN2A SCN5A	5.58e-05	201	22	4	GO:0001508
GeneOntologyBiologicalProcess	sodium ion transmembrane transport	CACNA1I SCN11A SCN2A SCN5A	6.37e-05	208	22	4	GO:0035725
GeneOntologyBiologicalProcess	cardiac muscle cell action potential	SCN11A SCN2A SCN5A	1.05e-04	87	22	3	GO:0086001
GeneOntologyBiologicalProcess	cardiac muscle cell contraction	SCN11A SCN2A SCN5A	1.28e-04	93	22	3	GO:0086003
GeneOntologyBiologicalProcess	oocyte development	PRAMEF19 KMT2D PRAMEF18	1.55e-04	99	22	3	GO:0048599
GeneOntologyBiologicalProcess	oocyte differentiation	PRAMEF19 KMT2D PRAMEF18	1.74e-04	103	22	3	GO:0009994
GeneOntologyBiologicalProcess	sodium ion transport	CACNA1I SCN11A SCN2A SCN5A	1.87e-04	275	22	4	GO:0006814
GeneOntologyBiologicalProcess	cellular process involved in reproduction in multicellular organism	MTA2 DCST1 PRAMEF19 KMT2D PRAMEF18	1.96e-04	527	22	5	GO:0022412
GeneOntologyBiologicalProcess	actin-mediated cell contraction	SCN11A SCN2A SCN5A	3.22e-04	127	22	3	GO:0070252
GeneOntologyBiologicalProcess	regulation of cell fate specification	MTA2 MTA1	4.33e-04	29	22	2	GO:0042659
GeneOntologyBiologicalProcess	actin filament-based movement	SCN11A SCN2A SCN5A	5.56e-04	153	22	3	GO:0030048
GeneOntologyBiologicalProcess	oogenesis	PRAMEF19 KMT2D PRAMEF18	5.88e-04	156	22	3	GO:0048477
GeneOntologyBiologicalProcess	cardiac muscle contraction	SCN11A SCN2A SCN5A	7.17e-04	167	22	3	GO:0060048
GeneOntologyCellularComponent	voltage-gated sodium channel complex	CACNA1I SCN11A SCN2A SCN5A	2.17e-09	17	22	4	GO:0001518
GeneOntologyCellularComponent	sodium channel complex	CACNA1I SCN11A SCN2A SCN5A	2.15e-08	29	22	4	GO:0034706
GeneOntologyCellularComponent	cation channel complex	CACNA1I SCN11A SCN2A SCN5A	9.71e-05	235	22	4	GO:0034703
GeneOntologyCellularComponent	NuRD complex	MTA2 MTA1	1.42e-04	17	22	2	GO:0016581
GeneOntologyCellularComponent	CHD-type complex	MTA2 MTA1	1.42e-04	17	22	2	GO:0090545
GeneOntologyCellularComponent	monoatomic ion channel complex	CACNA1I SCN11A SCN2A SCN5A	5.95e-04	378	22	4	GO:0034702
GeneOntologyCellularComponent	Cul2-RING ubiquitin ligase complex	PRAMEF19 PRAMEF18	1.11e-03	47	22	2	GO:0031462
GeneOntologyCellularComponent	acrosomal vesicle	DCST1 PRAMEF19 PRAMEF18	1.26e-03	206	22	3	GO:0001669
GeneOntologyCellularComponent	transmembrane transporter complex	CACNA1I SCN11A SCN2A SCN5A	1.98e-03	523	22	4	GO:1902495
GeneOntologyCellularComponent	intercalated disc	SCN2A SCN5A	2.31e-03	68	22	2	GO:0014704
GeneOntologyCellularComponent	transporter complex	CACNA1I SCN11A SCN2A SCN5A	2.38e-03	550	22	4	GO:1990351
GeneOntologyCellularComponent	transferase complex	CCNE1 PRAMEF19 ASB1 KMT2D PRAMEF18	2.81e-03	963	22	5	GO:1990234
GeneOntologyCellularComponent	T-tubule	SCN2A SCN5A	3.10e-03	79	22	2	GO:0030315
GeneOntologyCellularComponent	histone deacetylase complex	MTA2 MTA1	3.58e-03	85	22	2	GO:0000118
GeneOntologyCellularComponent	cell-cell contact zone	SCN2A SCN5A	4.36e-03	94	22	2	GO:0044291
GeneOntologyCellularComponent	SWI/SNF superfamily-type complex	MTA2 MTA1	4.54e-03	96	22	2	GO:0070603
GeneOntologyCellularComponent	ubiquitin ligase complex	PRAMEF19 ASB1 PRAMEF18	5.75e-03	352	22	3	GO:0000151
GeneOntologyCellularComponent	ATPase complex	MTA2 MTA1	8.05e-03	129	22	2	GO:1904949
GeneOntologyCellularComponent	plasma membrane protein complex	CACNA1I SCN11A SCN2A SCN5A	8.41e-03	785	22	4	GO:0098797
MousePheno	abnormal action potential	CACNA1I SCN11A SCN2A SCN5A	5.02e-05	133	22	4	MP:0005402
Domain	Na_channel_asu	SCN11A SCN2A SCN5A	1.69e-07	10	22	3	IPR001696
Domain	Na_trans_assoc	SCN11A SCN2A SCN5A	1.69e-07	10	22	3	IPR010526
Domain	Na_trans_assoc	SCN11A SCN2A SCN5A	1.69e-07	10	22	3	PF06512
Domain	Channel_four-helix_dom	CACNA1I SCN11A SCN2A SCN5A	5.47e-07	57	22	4	IPR027359
Domain	-	CACNA1I SCN11A SCN2A SCN5A	5.47e-07	57	22	4	1.20.120.350
Domain	Ion_trans_dom	CACNA1I SCN11A SCN2A SCN5A	8.85e-06	114	22	4	IPR005821
Domain	Ion_trans	CACNA1I SCN11A SCN2A SCN5A	8.85e-06	114	22	4	PF00520
Domain	Na_trans_cytopl	SCN2A SCN5A	1.98e-05	6	22	2	PF11933
Domain	Na_trans_cytopl	SCN2A SCN5A	1.98e-05	6	22	2	IPR024583
Domain	BAH	MTA2 MTA1	7.24e-05	11	22	2	SM00439
Domain	BAH	MTA2 MTA1	7.24e-05	11	22	2	PF01426
Domain	BAH_dom	MTA2 MTA1	7.24e-05	11	22	2	IPR001025
Domain	BAH	MTA2 MTA1	7.24e-05	11	22	2	PS51038
Domain	ZnF_GATA	MTA2 MTA1	8.68e-05	12	22	2	SM00401
Domain	ELM2	MTA2 MTA1	1.03e-04	13	22	2	SM01189
Domain	ELM2	MTA2 MTA1	1.03e-04	13	22	2	PF01448
Domain	ELM2	MTA2 MTA1	1.03e-04	13	22	2	PS51156
Domain	ELM2_dom	MTA2 MTA1	1.03e-04	13	22	2	IPR000949
Domain	Znf_GATA	MTA2 MTA1	1.38e-04	15	22	2	IPR000679
Domain	GATA	MTA2 MTA1	1.38e-04	15	22	2	PF00320
Domain	GATA_ZN_FINGER_1	MTA2 MTA1	1.57e-04	16	22	2	PS00344
Domain	GATA_ZN_FINGER_2	MTA2 MTA1	1.57e-04	16	22	2	PS50114
Domain	PRAME_family	PRAMEF19 PRAMEF18	2.24e-04	19	22	2	IPR026271
Domain	SANT_dom	MTA2 MTA1	4.23e-04	26	22	2	IPR017884
Domain	SANT	MTA2 MTA1	4.91e-04	28	22	2	PS51293
Domain	Znf_FYVE_PHD	RFFL KDM5C KMT2D	6.59e-04	147	22	3	IPR011011
Domain	Myb_DNA-binding	MTA2 MTA1	7.70e-04	35	22	2	PF00249
Domain	MYB_LIKE	MTA2 MTA1	9.08e-04	38	22	2	PS50090
Domain	SANT	MTA2 MTA1	1.57e-03	50	22	2	SM00717
Domain	SANT/Myb	MTA2 MTA1	1.69e-03	52	22	2	IPR001005
Domain	PHD	KDM5C KMT2D	3.49e-03	75	22	2	PF00628
Domain	Znf_PHD-finger	KDM5C KMT2D	3.86e-03	79	22	2	IPR019787
Domain	IQ	SCN2A SCN5A	4.06e-03	81	22	2	SM00015
Domain	ZF_RING_1	DCST1 RFFL KMT2D	4.63e-03	291	22	3	PS00518
Domain	PHD	KDM5C KMT2D	4.87e-03	89	22	2	SM00249
Domain	ZF_RING_2	DCST1 RFFL KMT2D	4.95e-03	298	22	3	PS50089
Domain	IQ_motif_EF-hand-BS	SCN2A SCN5A	4.98e-03	90	22	2	IPR000048
Domain	Znf_PHD	KDM5C KMT2D	5.09e-03	91	22	2	IPR001965
Domain	RING	DCST1 RFFL KMT2D	5.28e-03	305	22	3	SM00184
Domain	IQ	SCN2A SCN5A	5.31e-03	93	22	2	PS50096
Domain	ZF_PHD_2	KDM5C KMT2D	5.53e-03	95	22	2	PS50016
Domain	ZF_PHD_1	KDM5C KMT2D	5.65e-03	96	22	2	PS01359
Domain	Znf_RING	DCST1 RFFL KMT2D	6.34e-03	326	22	3	IPR001841
Domain	-	RFFL KDM5C KMT2D	1.51e-02	449	22	3	3.30.40.10
Domain	Znf_RING/FYVE/PHD	RFFL KDM5C KMT2D	1.60e-02	459	22	3	IPR013083
Pathway	REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS	SCN11A SCN2A SCN5A	6.41e-06	31	17	3	M877
Pathway	REACTOME_PHASE_0_RAPID_DEPOLARISATION	SCN11A SCN2A SCN5A	7.07e-06	32	17	3	M27455
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	MTA2 KDM5C KMT2D MTA1	4.81e-05	175	17	4	MM14941
Pathway	REACTOME_MUSCLE_CONTRACTION	CACNA1I SCN11A SCN2A SCN5A	8.58e-05	203	17	4	M5485
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	MTA2 KDM5C KMT2D MTA1	2.65e-04	272	17	4	M29619
Pathway	REACTOME_L1CAM_INTERACTIONS	SCN11A SCN2A SCN5A	3.84e-04	121	17	3	M872
Pathway	WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY	MTA2 KDM5C KMT2D MTA1	3.89e-04	301	17	4	MM15983
Pathway	REACTOME_REGULATION_OF_PTEN_GENE_TRANSCRIPTION	MTA2 MTA1	4.72e-04	27	17	2	MM15537
Pathway	REACTOME_CARDIAC_CONDUCTION	SCN11A SCN2A SCN5A	4.74e-04	130	17	3	M27454
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_OF_BROWN_AND_BEIGE_ADIPOCYTE_DIFFERENTIATION	MTA2 MTA1	6.24e-04	31	17	2	M48258
Pathway	REACTOME_DEVELOPMENTAL_BIOLOGY	MTA2 CACNA1I SCN11A KMT2D SCN2A MTA1 SCN5A	8.54e-04	1432	17	7	M509
Pathway	WP_EFFECT_OF_PROGERIN_ON_GENES_INVOLVED_IN_PROGERIA	MTA2 MTA1	8.89e-04	37	17	2	M39756
Pathway	REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION	MTA2 MTA1	1.43e-03	47	17	2	MM15428
Pathway	REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION_INITIATION	MTA2 MTA1	1.43e-03	47	17	2	M1095
Pathway	REACTOME_HDACS_DEACETYLATE_HISTONES	MTA2 MTA1	1.96e-03	55	17	2	MM14932
Pathway	REACTOME_REGULATION_OF_PTEN_GENE_TRANSCRIPTION	MTA2 MTA1	2.40e-03	61	17	2	M27811
Pubmed	International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels.	SCN11A SCN2A SCN5A	1.84e-08	9	22	3	16382098
Pubmed	Overexpression of MTA1 inhibits the metastatic ability of ZR-75-30 cells in vitro by promoting MTA2 degradation.	MTA2 MTA1	3.82e-07	2	22	2	30642362
Pubmed	Isoform-specific effects of the beta2 subunit on voltage-gated sodium channel gating.	SCN2A SCN5A	3.82e-07	2	22	2	16847056
Pubmed	Assignment of the metastasis-associated gene (Mta1) to mouse chromosome band 12F and the metastasis-associated gene 2 (Mta2) to mouse chromosome band 19B by fluorescence in situ hybridization.	MTA2 MTA1	3.82e-07	2	22	2	11856890
Pubmed	Specialized functions of Nav1.5 and Nav1.9 channels in electrogenesis of myenteric neurons in intact mouse ganglia.	SCN11A SCN5A	3.82e-07	2	22	2	24719102
Pubmed	The expansion of the PRAME gene family in Eutheria.	PRAMEF19 PRAMEF18	1.15e-06	3	22	2	21347312
Pubmed	Identification and characterization of metastasis-associated gene/protein 1 (MTA1).	MTA2 MTA1	1.15e-06	3	22	2	25315816
Pubmed	Calmodulin mediates Ca2+ sensitivity of sodium channels.	SCN2A SCN5A	1.15e-06	3	22	2	15316014
Pubmed	Structure, expression and functions of MTA genes.	MTA2 MTA1	1.15e-06	3	22	2	26869315
Pubmed	Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse.	PRAMEF19 MTA1 PRAMEF18	1.42e-06	35	22	3	19389355
Pubmed	The Epigenetic Factor Landscape of Developing Neocortex Is Regulated by Transcription Factors Pax6→ Tbr2→ Tbr1.	MTA2 KDM5C KMT2D MTA1	2.74e-06	157	22	4	30186101
Pubmed	The Nucleosome Remodelling and Deacetylation complex suppresses transcriptional noise during lineage commitment.	MTA2 MTA1	3.82e-06	5	22	2	31036553
Pubmed	Structural analyses of Ca²⁺/CaM interaction with NaV channel C-termini reveal mechanisms of calcium-dependent regulation.	SCN2A SCN5A	3.82e-06	5	22	2	25232683
Pubmed	The NuRD component Mbd3 is required for pluripotency of embryonic stem cells.	MTA2 MTA1	3.82e-06	5	22	2	16462733
Pubmed	Duplication and positive selection among hominin-specific PRAME genes.	PRAMEF19 PRAMEF18	3.82e-06	5	22	2	16159394
Pubmed	Early development of electrical excitability in the mouse enteric nervous system.	SCN11A SCN5A	3.82e-06	5	22	2	22875929
Pubmed	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels.	SCN2A SCN5A	3.82e-06	5	22	2	17724025
Pubmed	Murine Sall1 represses transcription by recruiting a histone deacetylase complex.	MTA2 MTA1	5.72e-06	6	22	2	11836251
Pubmed	Are voltage-dependent ion channels involved in the endothelial cell control of vasomotor tone?	SCN11A SCN2A	5.72e-06	6	22	2	17513486
Pubmed	Molecular association between ATR and two components of the nucleosome remodeling and deacetylating complex, HDAC2 and CHD4.	MTA2 MTA1	8.01e-06	7	22	2	10545197
Pubmed	Atypical Mowat-Wilson patient confirms the importance of the novel association between ZFHX1B/SIP1 and NuRD corepressor complex.	MTA2 MTA1	1.07e-05	8	22	2	18182442
Pubmed	Atrophin recruits HDAC1/2 and G9a to modify histone H3K9 and to determine cell fates.	MTA2 MTA1	1.07e-05	8	22	2	18451879
Pubmed	The zinc finger and C-terminal domains of MTA proteins are required for FOG-2-mediated transcriptional repression via the NuRD complex.	MTA2 MTA1	1.07e-05	8	22	2	18067919
Pubmed	Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions.	KDM5C KMT2D NF1	1.22e-05	71	22	3	28319113
Pubmed	Histone demethylase KDM5C is a SAHA-sensitive central hub at the crossroads of transcriptional axes involved in multiple neurodevelopmental disorders.	KDM5C SCN2A	1.37e-05	9	22	2	31691806
Pubmed	Expression pattern of neuronal and skeletal muscle voltage-gated Na+ channels in the developing mouse heart.	SCN2A SCN5A	1.37e-05	9	22	2	15746173
Pubmed	RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene.	MTA2 MTA1	1.37e-05	9	22	2	22926524
Pubmed	Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis.	MTA2 MTA1	1.37e-05	9	22	2	26028330
Pubmed	PWWP2B Fine-Tunes Adipose Thermogenesis by Stabilizing HDACs in a NuRD Subcomplex.	MTA2 MTA1	1.71e-05	10	22	2	34180153
Pubmed	Increased interaction between DJ-1 and the Mi-2/ nucleosome remodelling and deacetylase complex during cellular stress.	MTA2 MTA1	1.71e-05	10	22	2	20127688
Pubmed	BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter.	MTA2 MTA1	1.71e-05	10	22	2	16091750
Pubmed	MBD3L1 is a transcriptional repressor that interacts with methyl-CpG-binding protein 2 (MBD2) and components of the NuRD complex.	MTA2 MTA1	2.09e-05	11	22	2	15456747
Pubmed	Translational isoforms of FOG1 regulate GATA1-interacting complexes.	MTA2 MTA1	2.09e-05	11	22	2	19654328
Pubmed	NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity and lineage commitment.	MTA2 MTA1	2.51e-05	12	22	2	22560079
Pubmed	Metastasis tumor antigen 2 (MTA2) is involved in proper imprinted expression of H19 and Peg3 during mouse preimplantation development.	MTA2 MTA1	2.51e-05	12	22	2	20720167
Pubmed	The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.	MTA2 MTA1	2.51e-05	12	22	2	23708667
Pubmed	Nav1.2 haplodeficiency in excitatory neurons causes absence-like seizures in mice.	SCN2A SCN5A	2.51e-05	12	22	2	30175250
Pubmed	Genome-wide association study of height and body mass index in Australian twin families.	ADAMTSL3 FTO	2.51e-05	12	22	2	20397748
Pubmed	NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities.	MTA2 MTA1	2.51e-05	12	22	2	9885572
Pubmed	LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer.	MTA2 MTA1	2.97e-05	13	22	2	19703393
Pubmed	Regulation of neuronal voltage-gated sodium channels by the ubiquitin-protein ligases Nedd4 and Nedd4-2.	SCN2A SCN5A	2.97e-05	13	22	2	15123669
Pubmed	The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity.	MTA2 MTA1	2.97e-05	13	22	2	12920132
Pubmed	MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties.	MTA2 MTA1	3.46e-05	14	22	2	16428440
Pubmed	NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination.	MTA2 MTA1	3.46e-05	14	22	2	25150861
Pubmed	Human cytomegalovirus UL29/28 protein interacts with components of the NuRD complex which promote accumulation of immediate-early RNA.	MTA2 MTA1	3.46e-05	14	22	2	20585571
Pubmed	NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development.	MTA2 MTA1	3.99e-05	15	22	2	19927129
Pubmed	The chromatin remodeling factor CHD5 is a transcriptional repressor of WEE1.	MTA2 MTA1	3.99e-05	15	22	2	25247294
Pubmed	MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing.	MTA2 MTA1	3.99e-05	15	22	2	15701600
Pubmed	Differential expression of PRAMEL1, a cancer/testis antigen, during spermatogenesis in the mouse.	PRAMEF19 PRAMEF18	5.16e-05	17	22	2	23565261
Pubmed	Mouse Pramel1 regulates spermatogonial development by inhibiting retinoic acid signaling during spermatogenesis.	PRAMEF19 PRAMEF18	5.16e-05	17	22	2	37781892
Pubmed	Examining post-translational modification-mediated protein-protein interactions using a chemical proteomics approach.	MTA2 MTA1	5.16e-05	17	22	2	23281010
Pubmed	A Functional Switch of NuRD Chromatin Remodeling Complex Subunits Regulates Mouse Cortical Development.	MTA2 MTA1	5.16e-05	17	22	2	27806305
Pubmed	Oocyte-specific gene Oog1 suppresses the expression of spermatogenesis-specific genes in oocytes.	PRAMEF19 PRAMEF18	5.81e-05	18	22	2	29731491
Pubmed	The promoter of the oocyte-specific gene, Oog1, functions in both male and female meiotic germ cells in transgenic mice.	PRAMEF19 PRAMEF18	5.81e-05	18	22	2	23894331
Pubmed	Identification of a new expanding family of genes characterized by atypical LRR domains. Localization of a cluster preferentially expressed in oocyte.	PRAMEF19 PRAMEF18	5.81e-05	18	22	2	14675769
Pubmed	Mi-2/NuRD is required in renal progenitor cells during embryonic kidney development.	MTA2 MTA1	5.81e-05	18	22	2	23201013
Pubmed	Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation.	MTA2 MTA1	5.81e-05	18	22	2	10444591
Pubmed	The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.	MTA2 MTA1	5.81e-05	18	22	2	9790534
Pubmed	A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes.	MTA2 MTA1	5.81e-05	18	22	2	12493763
Pubmed	An enhancer cluster controls gene activity and topology of the SCN5A-SCN10A locus in vivo.	SCN11A SCN5A	5.81e-05	18	22	2	31666509
Pubmed	Oogenesin is a novel mouse protein expressed in oocytes and early cleavage-stage embryos.	PRAMEF19 PRAMEF18	5.81e-05	18	22	2	12890732
Pubmed	Pramel15 facilitates zygotic nuclear DNMT1 degradation and DNA demethylation.	PRAMEF19 PRAMEF18	5.81e-05	18	22	2	39181896
Pubmed	Pramel7 mediates ground-state pluripotency through proteasomal-epigenetic combined pathways.	PRAMEF19 PRAMEF18	6.49e-05	19	22	2	28604677
Pubmed	Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.	PRAMEF19 PRAMEF18	7.21e-05	20	22	2	26694250
Pubmed	Oog1, an oocyte-specific protein, interacts with Ras and Ras-signaling proteins during early embryogenesis.	PRAMEF19 PRAMEF18	7.21e-05	20	22	2	16580637
Pubmed	FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis.	MTA2 MTA1	7.21e-05	20	22	2	27773593
Pubmed	Pramel7 mediates LIF/STAT3-dependent self-renewal in embryonic stem cells.	PRAMEF19 PRAMEF18	7.21e-05	20	22	2	21425410
Pubmed	Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.	KDM5C KMT2D	7.96e-05	21	22	2	27626377
Pubmed	Sertoli cell-only phenotype and scRNA-seq define PRAMEF12 as a factor essential for spermatogenesis in mice.	PRAMEF19 PRAMEF18	8.76e-05	22	22	2	31729367
Pubmed	Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.	MTA2 MTA1	9.59e-05	23	22	2	21670149
Pubmed	Oogenesis specific genes (Nobox, Oct4, Bmp15, Gdf9, Oogenesin1 and Oogenesin2) are differentially expressed during natural and gonadotropin-induced mouse follicular development.	PRAMEF19 PRAMEF18	9.59e-05	23	22	2	19480014
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	RFFL KDM5C KMT2D MTA1 NF1	1.04e-04	774	22	5	15302935
Pubmed	Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells.	MTA2 MTA1	1.05e-04	24	22	2	18454139
Pubmed	MAGE-B4, a binding partner of PRAMEF12, is dispensable for spermatogenesis and male fertility in mice.	PRAMEF19 PRAMEF18	1.14e-04	25	22	2	37451217
Pubmed	Common variants at ten loci influence QT interval duration in the QTGEN Study.	RFFL SCN5A	1.14e-04	25	22	2	19305408
Pubmed	Incomplete reactivation of Oct4-related genes in mouse embryos cloned from somatic nuclei.	PRAMEF19 PRAMEF18	1.14e-04	25	22	2	12620990
Pubmed	Expression profiling in transgenic FVB/N embryonic stem cells overexpressing STAT3.	PRAMEF19 PRAMEF18	1.23e-04	26	22	2	18500982
Pubmed	SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis.	MTA2 MTA1	1.43e-04	28	22	2	34163012
Pubmed	Differences in gene expression between mouse and human for dynamically regulated genes in early embryo.	PRAMEF19 PRAMEF18	1.43e-04	28	22	2	25089626
Pubmed	An Oct4-centered protein interaction network in embryonic stem cells.	MTA2 KMT2D MTA1	1.57e-04	167	22	3	20362541
Pubmed	Thirteen Ovary-Enriched Genes Are Individually Not Essential for Female Fertility in Mice.	PRAMEF19 PRAMEF18	1.64e-04	30	22	2	38786026
Pubmed	PHD finger protein 1 (PHF1) is a novel reader for histone H4R3 symmetric dimethylation and coordinates with PRMT5-WDR77/CRL4B complex to promote tumorigenesis.	MTA2 MTA1	1.76e-04	31	22	2	29846670
Pubmed	LSM14B is essential for oocyte meiotic maturation by regulating maternal mRNA storage and clearance.	PRAMEF19 PRAMEF18	1.87e-04	32	22	2	37889087
Pubmed	A genome-wide association study in 19 633 Japanese subjects identified LHX3-QSOX2 and IGF1 as adult height loci.	ADAMTSL3 DGKH	2.12e-04	34	22	2	20189936
Pubmed	Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors.	MTA2 MTA1	2.24e-04	35	22	2	22325351
Pubmed	Cross-linking mass spectrometry reveals the structural topology of peripheral NuRD subunits relative to the core complex.	MTA2 MTA1	2.65e-04	38	22	2	33283408
Pubmed	Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.	MTA2 MTA1	3.72e-04	45	22	2	21258344
Pubmed	Mbd3, a component of the NuRD co-repressor complex, is required for development of pluripotent cells.	PRAMEF19 PRAMEF18	3.89e-04	46	22	2	17287250
Pubmed	DUX is a non-essential synchronizer of zygotic genome activation.	PRAMEF19 PRAMEF18	4.59e-04	50	22	2	31806660
Pubmed	The polycomb group protein L3mbtl2 assembles an atypical PRC1-family complex that is essential in pluripotent stem cells and early development.	MTA2 KDM5C	4.78e-04	51	22	2	22770845
Pubmed	Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes.	MTA2 MTA1	5.16e-04	53	22	2	21532573
Pubmed	CUL4B Promotes Breast Carcinogenesis by Coordinating with Transcriptional Repressor Complexes in Response to Hypoxia Signaling Pathway.	MTA2 MTA1	5.16e-04	53	22	2	34026424
Pubmed	Proteomic analysis of DZIP3 interactome and its role in proliferation and metastasis in gastric cancer cells.	MTA2 MTA1	5.16e-04	53	22	2	36841324
Pubmed	New nomenclature for chromatin-modifying enzymes.	KDM5C KMT2D	5.97e-04	57	22	2	18022353
Pubmed	ZAR1 and ZAR2 are required for oocyte meiotic maturation by regulating the maternal transcriptome and mRNA translational activation.	PRAMEF19 PRAMEF18	6.18e-04	58	22	2	31598710
Interaction	BRCA2 interactions	CCNE1 MTA2 DGKH KDM5C MTA1	3.00e-05	384	20	5	int:BRCA2
Interaction	SCN10A interactions	SCN11A SCN5A	5.12e-05	11	20	2	int:SCN10A
Interaction	ATXN3L interactions	MTA2 RFFL	5.12e-05	11	20	2	int:ATXN3L
Interaction	NFE2 interactions	ASB1 KDM5C KMT2D	7.57e-05	84	20	3	int:NFE2
Interaction	NALCN interactions	SCN11A SCN5A	8.45e-05	14	20	2	int:NALCN
Interaction	SCN11A interactions	SCN11A SCN5A	9.75e-05	15	20	2	int:SCN11A
Interaction	LIN37 interactions	CCNE1 MTA2 MTA1	1.02e-04	93	20	3	int:LIN37
Interaction	SCN8A interactions	SCN11A SCN5A	1.76e-04	20	20	2	int:SCN8A
Interaction	SCN9A interactions	SCN11A SCN5A	1.94e-04	21	20	2	int:SCN9A
Interaction	ZFPM1 interactions	MTA2 MTA1	2.14e-04	22	20	2	int:ZFPM1
Interaction	CACNA1D interactions	SCN11A SCN5A	2.55e-04	24	20	2	int:CACNA1D
Interaction	ZMYM3 interactions	MTA2 MTA1 FTO	3.22e-04	137	20	3	int:ZMYM3
Interaction	ZFPM2 interactions	MTA2 MTA1	3.48e-04	28	20	2	int:ZFPM2
Interaction	SCN1A interactions	SCN11A SCN5A	3.74e-04	29	20	2	int:SCN1A
Interaction	ZNF827 interactions	MTA2 MTA1	3.74e-04	29	20	2	int:ZNF827
Interaction	SIN3B interactions	MTA2 SCN2A MTA1	3.96e-04	147	20	3	int:SIN3B
Interaction	TCF19 interactions	MTA2 MTA1	4.56e-04	32	20	2	int:TCF19
Interaction	H3C14 interactions	MTA2 KMT2D MTA1	4.71e-04	156	20	3	int:H3C14
Interaction	MBD2 interactions	MTA2 KDM5C MTA1	5.16e-04	161	20	3	int:MBD2
Interaction	MYBL2 interactions	CCNE1 MTA2 MTA1	5.26e-04	162	20	3	int:MYBL2
Interaction	E2F5 interactions	CCNE1 KMT2D	5.78e-04	36	20	2	int:E2F5
Interaction	CACNA1B interactions	SCN11A SCN5A	6.10e-04	37	20	2	int:CACNA1B
Interaction	H3C10 interactions	MTA2 MTA1	6.44e-04	38	20	2	int:H3C10
Interaction	PIMREG interactions	MTA2 MTA1	7.14e-04	40	20	2	int:PIMREG
Interaction	MBD3L2 interactions	MTA2 MTA1	7.50e-04	41	20	2	int:MBD3L2
Interaction	CPNE5 interactions	MTA2 MTA1	7.87e-04	42	20	2	int:CPNE5
Interaction	H3C12 interactions	MTA2 MTA1	8.25e-04	43	20	2	int:H3C12
Interaction	ZMYND8 interactions	MTA2 KDM5C MTA1	8.48e-04	191	20	3	int:ZMYND8
Interaction	CARTPT interactions	KDM5C FTO	9.03e-04	45	20	2	int:CARTPT
Interaction	SCN5A interactions	SCN11A SCN5A	9.85e-04	47	20	2	int:SCN5A
Interaction	SMARCA4 interactions	CCNE1 MTA2 KDM5C NF1	9.87e-04	462	20	4	int:SMARCA4
Interaction	DPY30 interactions	MTA2 KMT2D MTA1	1.03e-03	204	20	3	int:DPY30
Interaction	NACC2 interactions	MTA2 MTA1	1.03e-03	48	20	2	int:NACC2
Interaction	CDK2AP2 interactions	MTA2 MTA1	1.07e-03	49	20	2	int:CDK2AP2
Interaction	FAM219A interactions	MTA2 MTA1	1.11e-03	50	20	2	int:FAM219A
Interaction	LIN52 interactions	MTA2 MTA1	1.16e-03	51	20	2	int:LIN52
Interaction	E2F2 interactions	CCNE1 KMT2D	1.35e-03	55	20	2	int:E2F2
Interaction	FOXK2 interactions	MTA2 KMT2D MTA1	1.36e-03	225	20	3	int:FOXK2
Cytoband	1p36.21	PRAMEF19 PRAMEF18	4.21e-04	63	22	2	1p36.21
Cytoband	Ensembl 112 genes in cytogenetic band chr3p22	SCN11A SCN5A	3.50e-03	184	22	2	chr3p22
Cytoband	Ensembl 112 genes in cytogenetic band chr1p36	PRAMEF19 GPR153 PRAMEF18	4.06e-03	681	22	3	chr1p36
GeneFamily	Sodium voltage-gated channel alpha subunits	SCN11A SCN2A SCN5A	8.23e-08	9	19	3	1203
GeneFamily	PHD finger proteins\|NuRD complex	MTA2 MTA1	6.86e-05	12	19	2	1305
GeneFamily	GATA zinc finger domain containing\|Myb/SANT domain containing	MTA2 MTA1	1.09e-04	15	19	2	82
GeneFamily	PRAME family	PRAMEF19 PRAMEF18	2.85e-04	24	19	2	686
GeneFamily	GATA zinc finger domain containing\|Myb/SANT domain containing	MTA2 MTA1	1.40e-03	53	19	2	532
GeneFamily	PHD finger proteins	KDM5C KMT2D	3.97e-03	90	19	2	88
ToppCell	wk_15-18-Epithelial-PNS-Schwann_precursor\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	KMT2D SCN5A NF1	8.72e-05	177	22	3	5357359e6c2161a37f39a6b3b78449f5cbc327d1
ToppCell	facs-Heart-LV-3m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.11e-04	192	22	3	840a34c1b82d218be999ab5e1bcafd6370d7a4b1
ToppCell	facs-Pancreas-Exocrine-3m-Mesenchymal-pancreatic_stellate_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.11e-04	192	22	3	8937a59f6bbe07f671bdabbd3707dc9c17a14cd9
ToppCell	facs-Pancreas-Exocrine-3m-Mesenchymal-pancreatic_stellate_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.11e-04	192	22	3	ac1477433704573f95111eee6263b93668d2845e
ToppCell	facs-Heart-LV-3m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.11e-04	192	22	3	671d4e1eee5aba03c43dbc98f4b51ce42b3df5d5
ToppCell	facs-Pancreas-Exocrine-3m-Mesenchymal\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.11e-04	192	22	3	e4a7f2673f801b008ca67291db2fb2b9fd2955b8
ToppCell	droplet-Lung-30m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ACKR4 ADAMTSL3 GPR153	1.13e-04	193	22	3	64edc1d6fb0fe117767d494cf4a5723bf8be2804
ToppCell	droplet-Fat-Mat-18m-Mesenchymal\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.13e-04	193	22	3	ebd090d7801480b3cee45caac3d30cc991836769
ToppCell	droplet-Fat-Mat-18m-Mesenchymal-Cd34+\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.13e-04	193	22	3	22c58032e58730715224d7934968ce92d150b0e8
ToppCell	droplet-Fat-Mat-18m-Mesenchymal-mesenchymal_stem_cell_of_adipose\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACKR4 ADAMTSL3 GPR153	1.13e-04	193	22	3	573ad2f848bede1fe20c7b4b352a9242ec294725
Drug	Zonisamide	CACNA1I SCN11A SCN2A SCN5A	1.26e-09	17	21	4	DB00909
Drug	Benzylpenicillin sodium [69-57-8]; Up 200; 11.2uM; MCF7; HT_HG-U133A	ADAMTSL3 CACNA1I SCN11A MTA1 SCN5A NF1	1.89e-08	197	21	6	3577_UP
Drug	trifluoperazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA	SCN11A GPR153 ASB1 KDM5C NF1	6.31e-07	186	21	5	1004_UP
Drug	Flumequine [42835-25-6]; Up 200; 15.4uM; MCF7; HT_HG-U133A	CACNA1I SCN11A MTA1 SCN5A NF1	8.38e-07	197	21	5	5529_UP
Drug	Canavanine sulfate monohydrate (L,+) [206996-57-8]; Up 200; 13.6uM; HL60; HT_HG-U133A	SCN11A GPR153 MTA1 SCN5A NF1	9.03e-07	200	21	5	2141_UP
Drug	6-methylenetestosterone acetate	MTA2 MTA1	1.21e-05	6	21	2	CID000159323
Drug	Halcinonide [3093-35-4]; Up 200; 8.8uM; HL60; HT_HG-U133A	MTA2 CACNA1I GPR153 NF1	2.22e-05	184	21	4	2185_UP
Drug	Cocaine	SCN11A SCN5A	2.26e-05	8	21	2	DB00907
Drug	SC-560; Up 200; 10uM; PC3; HT_HG-U133A	MTA2 MTA1 NF1 APOL6	2.84e-05	196	21	4	6865_UP
Drug	Ethisterone [434-03-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A	MTA2 SCN11A MTA1 NF1	2.90e-05	197	21	4	2326_DN
Drug	Vidarabine [5536-17-4]; Up 200; 15uM; PC3; HT_HG-U133A	CCNE1 SCN11A KDM5C MTA1	2.90e-05	197	21	4	5850_UP
Drug	Captopril [62571-86-2]; Up 200; 17.2uM; PC3; HT_HG-U133A	MTA2 CACNA1I KDM5C APOL6	2.90e-05	197	21	4	4585_UP
Drug	Tetramisole hydrochloride [16595-80-5]; Up 200; 16.6uM; PC3; HT_HG-U133A	MTA2 CACNA1I ASB1 NF1	2.90e-05	197	21	4	4587_UP
Drug	clozapine; Down 200; 10uM; MCF7; HT_HG-U133A	ADAMTSL3 GPR153 KDM5C NF1	2.90e-05	197	21	4	5589_DN
Drug	Dinoprost trometamol [38362-01-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A	GPR153 ASB1 MTA1 NF1	2.90e-05	197	21	4	3308_DN
Drug	Suramin sodium salt; Up 200; 10uM; MCF7; HT_HG-U133A	MTA2 CACNA1I NF1 APOL6	2.96e-05	198	21	4	7524_UP
Drug	Chlormezanone [80-77-3]; Up 200; 14.6uM; MCF7; HT_HG-U133A	ADAMTSL3 SCN11A MTA1 SCN5A	2.96e-05	198	21	4	3235_UP
Drug	Hydroxyzine dihydrochloride [2192-20-3]; Up 200; 9uM; MCF7; HT_HG-U133A	MTA2 GPR153 MTA1 NF1	3.08e-05	200	21	4	1524_UP
Drug	Vitexin [3681-93-4]; Up 200; 9.2uM; PC3; HT_HG-U133A	MTA2 CACNA1I SCN11A NF1	3.08e-05	200	21	4	4588_UP
Drug	Sodium	SCN11A SCN2A SCN5A	6.14e-05	84	21	3	ctd:D012964
Drug	tetralol	CACNA1I SCN5A	6.28e-05	13	21	2	CID000010747
Drug	ethylnylestradiol	ACKR4 MTA2 CACNA1I MTA1 NF1 FTO APOL6	8.74e-05	1251	21	7	CID000003285
Drug	AC1NV99J	MTA2 MTA1	9.65e-05	16	21	2	CID005474719
Drug	Verapamil	CACNA1I SCN5A	9.65e-05	16	21	2	DB00661
Drug	pyraclofos	CACNA1I SCN2A SCN5A	1.23e-04	106	21	3	CID000093460
Drug	AC1L1EXH	MTA2 MTA1	1.23e-04	18	21	2	CID000002992
Drug	NSC3852	MTA2 MTA1	1.52e-04	20	21	2	CID000019103
Drug	lamotrigine	CACNA1I SCN2A SCN5A	1.60e-04	116	21	3	CID000003878
Drug	AC1L1EA5	MTA2 MTA1	2.21e-04	24	21	2	CID000002706
Drug	AC1NDLJ6	ACKR4 FTO	3.47e-04	30	21	2	CID004627775
Drug	oxcarbazepine	CACNA1I SCN5A	3.47e-04	30	21	2	CID000034312
Drug	procymidone	CCNE1 CACNA1I NF1	3.76e-04	155	21	3	ctd:C035988
Drug	tetradotoxin	CACNA1I SCN11A SCN2A SCN5A	5.72e-04	428	21	4	CID000020382
Drug	carbamazepine	SCN2A SCN5A APOL6	5.73e-04	179	21	3	CID000002554
Drug	ICI 182,780; Down 200; 0.01uM; MCF7; HT_HG-U133A	GPR153 KDM5C NF1	6.01e-04	182	21	3	1663_DN
Drug	NSC7524	CACNA1I SCN2A SCN5A	6.01e-04	182	21	3	CID000005657
Drug	Tetrodotoxin	SCN2A SCN5A	6.19e-04	40	21	2	ctd:D013779
Drug	ICI 182,780; Down 200; 0.01uM; MCF7; HT_HG-U133A	GPR153 ASB1 NF1	6.50e-04	187	21	3	5598_DN
Drug	wortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A	GPR153 MTA1 NF1	6.71e-04	189	21	3	7002_UP
Drug	Resveratrol [501-36-0]; Down 200; 17.6uM; PC3; HT_HG-U133A	MTA2 MTA1 NF1	6.71e-04	189	21	3	5084_DN
Drug	Ethisterone [434-03-7]; Down 200; 12.8uM; PC3; HT_HG-U133A	KDM5C MTA1 APOL6	6.81e-04	190	21	3	4340_DN
Drug	LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A_EA	CCNE1 MTA2 ASB1	6.81e-04	190	21	3	1016_DN
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Up 200; 5.2uM; MCF7; HT_HG-U133A	CACNA1I SCN11A NF1	6.81e-04	190	21	3	2887_UP
Drug	Mianserine hydrochloride [21535-47-7]; Up 200; 13.2uM; PC3; HT_HG-U133A	CACNA1I SCN11A KDM5C	6.81e-04	190	21	3	5786_UP
Drug	Metyrapone [54-36-4]; Up 200; 17.6uM; MCF7; HT_HG-U133A	CACNA1I SCN11A NF1	6.91e-04	191	21	3	5667_UP
Drug	Luteolin [491-70-3]; Down 200; 14uM; PC3; HT_HG-U133A	MTA2 ADAMTSL3 NF1	6.91e-04	191	21	3	6658_DN
Drug	Piperine [94-62-2]; Down 200; 14uM; PC3; HT_HG-U133A	ASB1 KDM5C MTA1	6.91e-04	191	21	3	4247_DN
Drug	Lasalocid sodium salt [25999-20-6]; Down 200; 6.6uM; PC3; HT_HG-U133A	CACNA1I ASB1 NF1	7.02e-04	192	21	3	6639_DN
Drug	Fludrocortisone acetate [514-36-3]; Down 200; 9.4uM; PC3; HT_HG-U133A	KDM5C MTA1 NF1	7.02e-04	192	21	3	4342_DN
Drug	Resveratrol [501-36-0]; Down 200; 17.6uM; MCF7; HT_HG-U133A	MTA2 ASB1 NF1	7.02e-04	192	21	3	2865_DN
Drug	Ricinine [524-40-3]; Down 200; 24.4uM; HL60; HT_HG-U133A	KDM5C NF1 APOL6	7.13e-04	193	21	3	2505_DN
Drug	Ketotifen fumarate [34580-14-8]; Down 200; 9.4uM; MCF7; HT_HG-U133A	CACNA1I KDM5C NF1	7.13e-04	193	21	3	3200_DN
Drug	Boldine [476-70-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A	CACNA1I NF1 APOL6	7.13e-04	193	21	3	4122_UP
Drug	Testosterone propionate [57-85-2]; Up 200; 11.6uM; PC3; HT_HG-U133A	SCN11A ASB1 NF1	7.13e-04	193	21	3	4676_UP
Drug	Terbutaline hemisulfate [23031-32-5]; Down 200; 7.2uM; PC3; HT_HG-U133A	SCN11A ASB1 NF1	7.13e-04	193	21	3	5764_DN
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; MCF7; HT_HG-U133A	CACNA1I KDM5C NF1	7.13e-04	193	21	3	6868_UP
Drug	Butylparaben [94-26-8]; Down 200; 20.6uM; MCF7; HT_HG-U133A	MTA2 CACNA1I KDM5C	7.13e-04	193	21	3	5608_DN
Drug	LY294002; Up 200; 10uM; MCF7; HG-U133A	CCNE1 NF1 APOL6	7.23e-04	194	21	3	258_UP
Drug	Carbachol [51-83-2]; Up 200; 21.8uM; MCF7; HT_HG-U133A	CACNA1I ASB1 MTA1	7.23e-04	194	21	3	5342_UP
Drug	Tenoxicam [59804-37-4]; Up 200; 11.8uM; MCF7; HT_HG-U133A	ADAMTSL3 CACNA1I SCN5A	7.23e-04	194	21	3	4182_UP
Drug	0317956-0000 [391210-11-0]; Down 200; 10uM; PC3; HT_HG-U133A	KDM5C MTA1 NF1	7.23e-04	194	21	3	4331_DN
Drug	Methazolamide [554-57-4]; Down 200; 17uM; PC3; HT_HG-U133A	MTA2 ASB1 NF1	7.23e-04	194	21	3	5794_DN
Drug	Atovaquone [95233-18-4]; Up 200; 11uM; MCF7; HT_HG-U133A	CACNA1I NF1 APOL6	7.23e-04	194	21	3	4786_UP
Drug	Naproxen [22204-53-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A	MTA2 ASB1 NF1	7.34e-04	195	21	3	1706_UP
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; HL60; HT_HG-U133A	MTA1 NF1 APOL6	7.34e-04	195	21	3	6174_DN
Drug	Perhexiline maleate [6724-53-4]; Down 200; 10.2uM; HL60; HT_HG-U133A	MTA2 ASB1 MTA1	7.34e-04	195	21	3	2410_DN
Drug	Tiapride hydrochloride [51012-33-0]; Down 200; 11uM; PC3; HT_HG-U133A	MTA2 NF1 APOL6	7.34e-04	195	21	3	3663_DN
Drug	Aminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A	MTA2 MTA1 NF1	7.34e-04	195	21	3	2313_DN
Drug	Azacyclonol [115-46-8]; Down 200; 15uM; MCF7; HT_HG-U133A	MTA2 SCN11A KDM5C	7.34e-04	195	21	3	1520_DN
Drug	Progesterone [57-83-0]; Up 200; 12.8uM; HL60; HT_HG-U133A	CACNA1I GPR153 NF1	7.34e-04	195	21	3	2426_UP
Drug	Sulfadiazine [68-35-9]; Down 200; 16uM; MCF7; HT_HG-U133A	CCNE1 GPR153 KDM5C	7.34e-04	195	21	3	1688_DN
Drug	Paclitaxel [33069-62-4]; Up 200; 4.6uM; MCF7; HT_HG-U133A	ASB1 MTA1 APOL6	7.34e-04	195	21	3	1542_UP
Drug	Pimethixene maleate [13187-06-9]; Down 200; 9.8uM; MCF7; HT_HG-U133A	GPR153 ASB1 NF1	7.34e-04	195	21	3	7426_DN
Drug	Triflusal [322-79-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A	GPR153 ASB1 NF1	7.34e-04	195	21	3	7451_DN
Drug	Trimethobenzamide hydrochloride [554-92-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A	SCN11A GPR153 NF1	7.34e-04	195	21	3	4180_DN
Drug	Ifenprodil tartrate [23210-58-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	CCNE1 GPR153 NF1	7.34e-04	195	21	3	7404_DN
Drug	Hemicholinium bromide [312-45-8]; Down 200; 7uM; PC3; HT_HG-U133A	CACNA1I SCN11A NF1	7.34e-04	195	21	3	6739_DN
Drug	Ethamsylate [2624-44-4]; Up 200; 15.2uM; PC3; HT_HG-U133A	MTA2 CACNA1I SCN2A	7.34e-04	195	21	3	4576_UP
Drug	radicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A	GPR153 KDM5C MTA1	7.34e-04	195	21	3	5579_DN
Drug	Scopoletin [92-61-5]; Down 200; 20.8uM; MCF7; HT_HG-U133A	GPR153 ASB1 NF1	7.34e-04	195	21	3	6510_DN
Drug	Gliclazide [21187-98-4]; Down 200; 12.4uM; PC3; HT_HG-U133A	MTA2 MTA1 APOL6	7.34e-04	195	21	3	5089_DN
Drug	Bufexamac [2438-72-4]; Down 200; 18uM; HL60; HT_HG-U133A	MTA2 KDM5C NF1	7.45e-04	196	21	3	2382_DN
Drug	Cephapirin sodium salt [24356-60-3]; Down 200; 9uM; MCF7; HT_HG-U133A	KDM5C MTA1 NF1	7.45e-04	196	21	3	3471_DN
Drug	Flutamide [13311-84-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A	MTA2 SCN11A APOL6	7.45e-04	196	21	3	4361_UP
Drug	Crotamiton [483-63-6]; Down 200; 19.6uM; PC3; HT_HG-U133A	CACNA1I MTA1 NF1	7.45e-04	196	21	3	4628_DN
Drug	Triamterene [396-01-0]; Up 200; 15.8uM; MCF7; HT_HG-U133A	GPR153 ASB1 MTA1	7.45e-04	196	21	3	1697_UP
Drug	Acetazolamide [59-66-5]; Up 200; 18uM; MCF7; HT_HG-U133A	GPR153 MTA1 NF1	7.45e-04	196	21	3	1686_UP
Drug	Vinpocetine [42971-09-5]; Up 200; 11.4uM; MCF7; HT_HG-U133A	CACNA1I MTA1 NF1	7.45e-04	196	21	3	7213_UP
Drug	Liothyronine [6893-02-3]; Down 200; 6.2uM; MCF7; HT_HG-U133A	GPR153 KDM5C NF1	7.45e-04	196	21	3	3324_DN
Drug	Seneciphylline [480-81-9]; Down 200; 12uM; PC3; HT_HG-U133A	SCN11A KDM5C MTA1	7.45e-04	196	21	3	4238_DN
Drug	wortmannin from Penicillium funiculosum; Down 200; 0.01uM; PC3; HT_HG-U133A	CCNE1 MTA2 NF1	7.45e-04	196	21	3	4467_DN
Drug	Lysergol [602-85-7]; Up 200; 15.8uM; MCF7; HT_HG-U133A	MTA2 CACNA1I NF1	7.45e-04	196	21	3	3261_UP
Drug	Novobiocin sodium salt [1476-53-5]; Down 200; 6.4uM; MCF7; HT_HG-U133A	CACNA1I GPR153 NF1	7.45e-04	196	21	3	4392_DN
Drug	Zuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	CCNE1 GPR153 MTA1	7.45e-04	196	21	3	7356_DN
Drug	Azathioprine [446-86-6]; Down 200; 14.4uM; PC3; HT_HG-U133A	MTA2 ASB1 NF1	7.45e-04	196	21	3	4667_DN
Drug	Sulfapyridine [144-83-2]; Up 200; 16uM; MCF7; HT_HG-U133A	SCN11A GPR153 NF1	7.45e-04	196	21	3	6101_UP
Drug	Primidone [125-33-7]; Up 200; 18.4uM; MCF7; HT_HG-U133A	MTA2 ASB1 NF1	7.45e-04	196	21	3	5323_UP
Drug	Labetalol hydrochloride [32780-64-6]; Down 200; 11uM; MCF7; HT_HG-U133A	GPR153 KDM5C NF1	7.45e-04	196	21	3	3167_DN
Drug	Nisoxetine hydrochloride [57754-86-6]; Down 200; 13uM; PC3; HT_HG-U133A	MTA2 ASB1 NF1	7.45e-04	196	21	3	5091_DN
Drug	Fluoxetine hydrochloride [59333-67-4]; Down 200; 11.6uM; PC3; HT_HG-U133A	CACNA1I NF1 APOL6	7.45e-04	196	21	3	6757_DN
Disease	generalized epilepsy with febrile seizures plus 2 (implicated_via_orthology)	SCN11A SCN2A SCN5A	3.19e-08	10	20	3	DOID:0111294 (implicated_via_orthology)
Disease	Dravet syndrome (implicated_via_orthology)	SCN11A SCN2A SCN5A	3.19e-08	10	20	3	DOID:0080422 (implicated_via_orthology)
Disease	generalized epilepsy with febrile seizures plus (implicated_via_orthology)	SCN11A SCN2A SCN5A	5.84e-08	12	20	3	DOID:0060170 (implicated_via_orthology)
Disease	Hereditary Paraganglioma-Pheochromocytoma Syndrome	KMT2D NF1	1.09e-04	23	20	2	C1708353
Disease	body fat percentage, coronary artery disease	DGKH FTO	1.19e-04	24	20	2	EFO_0001645, EFO_0007800
Disease	autism spectrum disorder (implicated_via_orthology)	KDM5C SCN2A TAFA3	1.43e-04	152	20	3	DOID:0060041 (implicated_via_orthology)
Disease	comparative body size at age 10, self-reported	ADAMTSL3 DGKH NF1 FTO	1.64e-04	420	20	4	EFO_0009819
Disease	epilepsy (implicated_via_orthology)	SCN11A SCN2A SCN5A	1.76e-04	163	20	3	DOID:1826 (implicated_via_orthology)
Disease	breast cancer (is_marker_for)	CCNE1 KDM5C KMT2D	2.56e-04	185	20	3	DOID:1612 (is_marker_for)
Disease	pulmonary function measurement, forced expiratory volume	DGKH ASB1	2.87e-04	37	20	2	EFO_0003892, EFO_0004314
Disease	abdominal adipose tissue measurement	ADAMTSL3 FTO	5.89e-04	53	20	2	EFO_0803316
Disease	sexual dimorphism measurement	CCNE1 ADAMTSL3 DCST1 NF1 FTO	7.10e-04	1106	20	5	EFO_0021796

Protein segments in the cluster

Peptide	Gene	Start	Entry
MWLWLCVCLCVCVYV	APOL6	326	Q9BWW8
INEKSVWCCGWLPCT	ASB1	66	Q9Y576
WCDIENCVKWMVPFA	CCNE1	321	P24864
MQCRLCASCWIYWKK	MTA2	386	O94776
GKPCWIICFCVWMAA	ACKR4	151	Q9NPB9
KCTDWWCQPMAQLEA	FTO	391	Q9C0B1
EIWNMCWLCMIVEFS	PRAMEF18	211	Q5VWM3
PWMALCVLWCSVAQA	GPR153	276	Q6NV75
DWKCLWCKTMVHTAC	DGKH	276	Q86XP1
WSCWDDMRQRCPVCT	DCST1	671	Q5T197
WCIKMVCNPWFECVS	CACNA1I	71	Q9P0X4
WWCQMEPCLPGEECK	TAFA3	96	Q7Z5A8
MWATCCNWFCLDGQP	RFFL	1	Q8WZ73
EIWNMCWPCMVAEVS	PRAMEF19	211	Q5SWL8
IWECCPLWMSIKQGV	SCN5A	696	Q14524
NMQCRLCASCWTYWK	MTA1	411	Q13330
KFANMCLIWDCCKPW	SCN2A	731	Q99250
CMRDIPTCKWLDQWT	NF1	2216	P21359
VWNCCPQWLCVKKVL	SCN11A	556	Q9UI33
LFDCPKWIAMEWSQC	ADAMTSL3	476	P82987
WEWDTKFLCPLCMRS	KDM5C	1236	P41229
KGGWKCKWCVSCMQC	KMT2D	1466	O14686